Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT05623319
Title Pembrolizumab and Olaparib Treatment of Extensive Small Cell Lung Cancer (ES-SCLC) (THOR)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Age Groups: adult | senior
Covered Countries ITA

No variant requirements are available.